Clinical trials are an important way to improve treatment for people with cancer. While most are continuing during the COVID-19 pandemic, the period of time that clinical trials are available and recruiting may change quickly. If you would like to get involved in a clinical trial, speak to your treatment team or the health service where the clinical trial is being undertaken, to confirm it is open and appropriate for you. For cancer information and support, call Cancer Council's experienced cancer nurses on 13 11 20 Monday to Friday from 9am-5pm.
This phase I/II dose escalation and expansion study is trying to understand how safe and effective a new drug (TAK-280) is in people with locally advanced or metastatic cancer that is unable to be removed with surgery
Status : Recruiting
This phase I study is evaluating how safe and effective a combination of two new cancer drugs (YH002 and YH001) are in people with advanced solid cancers
This phase I study is seeking to understand the appropriate dose level, safety and effectiveness of a new targeted therapy (D3S-001) in people with advanced solid cancers with the Kirsten rat sarcoma viral oncogene homolog gene (KRAS) p.G12C mutation
This phase I/II trial will begin to understand how safe and tolerable a new cancer drug (D-1553) is as a monotherapy and combination treatment for people with advanced solid cancers that have a KRasG12C mutation
This phase I study seeks to understand the safety of a new drug (ADG126) in people with cancers that are advanced and/or have spread to other parts of the body (metastatic)
This phase II trial is trying to determine how safe and tolerable a targeted therapy is for the treatment of several different cancer types
This phase I trial is evaluating a new targeted therapy in patients with advanced cancers and cancers that have spread to other parts of the body
This phase I/II study is trying to determine the best dose level and safety of a new treatment drug (PRS-344/S095012) in people with advanced or metastatic solid cancers
This phase II study is evaluating how safe and effective chemotherapy (belzutifan) is in combination with immunotherapy (pembrolizumab) and targeted therapy (lenvatinib) in people with multiple solid cancers, including cancer of the liver, bowel, pancreas, biliary tract, endometrium and oesophagus
This phase I study is seeking to determine the best dose level and effectiveness of a new targeted therapy (YH004) alone, and in combination with immunotherapy (toripalimab) in people with advanced solid cancers and relapsed or refractory non-Hodgkin lymphoma
Looking for a trial? Use the search functionality to find the trial you are finding.